The Future of Acute Wound Care

Promotes accelerated healing, reduces infection, minimizes scarring, and shortens hospital stay

Our mission is to help control global health care costs through faster and more effective, affordable acute wound care.

US Wound Co™ manages a portfolio of chronic wound care products to be marketed and sold under the name AcutaRex™.

The efficacy of the basic ingredients used in AcutaRex™ has been proven to assist in the rapid healing of accute wounds.

.

[/vc_column]

Everyday wounds,including most hospital surgeries and out-patient procedures will be greatly reduced in time required for closure by AcutaRex™ products.

About AcutaRex™

  • Total historical investment into current technology entity is approximately $145 million.
  • Current conservative replacement of expanded entity as of 2017 is estimated between $400 to $500 million in addition to 5-6 years for FDA regulatory approval.

  • AcutaRex™ utilizes a FDA 510(k) Acute Wound Care technology that is projected to expedite the wound site healing process significantly with better overall closes.

  • Wounds heal faster with full closure results with AcutaRex™
  • Acute wound care amounts to over 70% of the total wound care market compared to 30% for chronic care.
  • AcutaRex™ allows for substantial cost savings by reducing the time required for wound site closure.
  • AcutaRex™ is a product physicians and pharmacists can trust for their patients and customers health through consistent product performance.
  • The product is in a gel form and applied to topical wounds and surgical incisions.
  • A reduction in health care costs and the resulting private sector stimulus
  • Increased productivity in the workforce

Economic Benefits of AcutaRex™ according to US-Regional Impact Assessment Study by the prestigious Perryman Group.